Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
Vanderbilt University Medical Center
225 participants
Apr 27, 2022
OBSERVATIONAL
Conditions
Summary
This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators treat atrial fibrillation. The study will enroll 225 participants. Eligible participants will have undergone sequencing for arrhythmia and cardiomyopathy (CM) genes. Based on those results, participants will be recruited for an outpatient research visit with testing that includes cardiac MRI, rest/stress/signal-averaged ECGs, and cardiac monitoring. If an inherited arrhythmia/CM syndrome is diagnosed, guideline-directed changes to medical care will be recommended.
Eligibility
Inclusion Criteria8
- Minors \>15 years
- Adult \> 18 years
- Able to provide written informed consent
- Previously enrolled in the Vanderbilt Atrial Fibrillation Registry (IVR#020669)
- Atrial Fibrillation Ablation Registry (IRB#110881)
- Early-onset Atrial Fibrillation Registry (IRB#201666)
- Underwent whole genome sequencing/whole exome sequencing or clinical genetic testing and based on those results meets the genetic criteria for cases and controls as defined as a Cardiomyopathy (CM) Rare Variant (P/LP rare variant in CM gene, Arrhythmia Rare Variant (P/LP rare variant in arrhythmia gene), or a Control (no rare variant in CM, arrhythmia, or other Atrial Fibrillation gene).
- Diagnosis of Atrial Fibrillation prior to age of 65 (\</=65)
Exclusion Criteria1
- Pregnant women
Interventions
This is an observational study and there is no intervention.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05190679